|
gptkbp:instanceOf
|
gptkb:drug
antimalarial agent
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:CASNumber
|
351531-04-5
|
|
gptkbp:chemicalFormula
|
C19H28O5
|
|
gptkbp:developedBy
|
gptkb:artemisinin
|
|
gptkbp:discoveredBy
|
Arieh Zaritsky
Jacob Golenser
Kuninori Haynes
|
|
gptkbp:has_clinical_trial_status
|
investigational
|
|
gptkbp:has_improved_properties_over
|
gptkb:artemether
gptkb:artesunate
|
|
gptkbp:has_longer_half-life_than
|
gptkb:artemether
gptkb:artesunate
|
|
gptkbp:has_lower_neurotoxicity_than
|
gptkb:artemether
gptkb:artesunate
|
|
gptkbp:has_potential_use_for
|
gptkb:cancer
gptkb:toxoplasmosis
schistosomiasis
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Artemisone
|
|
gptkbp:is_not_approved_by
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:IUPACName
|
(10α,12β)-Dihydroartemisinin 10-(2-methoxyamino)propyl ether
|
|
gptkbp:mechanismOfAction
|
inhibits Plasmodium parasite
|
|
gptkbp:molecularWeight
|
336.42 g/mol
|
|
gptkbp:notableDerivative
|
gptkb:dihydroartemisinin
|
|
gptkbp:routeOfAdministration
|
oral
parenteral
|
|
gptkbp:usedFor
|
treatment of malaria
|
|
gptkbp:bfsParent
|
gptkb:ARTM
|
|
gptkbp:bfsLayer
|
8
|